Роль пролактину та діагностичне значення гіперпролактинемії у чоловіків
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Анотація
Верифікація клінічної причини і терапія патологічно підвищеного рівня пролактину є актуальною проблемою сучасної андрології, з якої все частіше стикається андролог і сексопатолог, що вимагає коректного і грамотного підходу в діагностиці та терапії даного стану.
##plugins.themes.bootstrap3.article.details##
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Автори зберігають авторське право, а також надають журналу право першого опублікування оригінальних наукових статей на умовах ліцензії Creative Commons Attribution 4.0 International License, що дозволяє іншим розповсюджувати роботу з визнанням авторства твору та першої публікації в цьому журналі.
Посилання
Сексология и андрология / под ред. А.Ф. Возианова, И.И. Горпинченко. – К.: Абрис, 1997. – 880 с.
Salais-López H, Agustín-Pavón C, Lanuza E, Martínez-García F. (2018) The maternal hormone in the male brain: Sexually dimorphic distribution of prolactin signalling in the mouse brain. PLoS One. Dec 20;13(12): e0208960. https://doi.org/10.1371/journal.pone.0208960
Татарчук Т.Ф., Гуньков С.В., Ефименко О.А. Современные подходы к диагностике и лечению гиперпролактинемии // Репродуктивная эндокринология. – 2012. – № 1. – С. 26–44. https://doi.org/10.18370/2309-4117.2012.3.26-44
Clapp C. et al. (2015) Regulation of blood vessels by prolactin and vasoinhibins // Advances in experimental medicine and biology. Vol. 846. – P. 83–95. https://doi.org/10.1007/978-3-319-12114-7_4
Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R et al. (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med; 44 (Suppl.):1075–84.
Majumdar A., Mangal N.S. (2013) Hyperprolactinemia J Hum Reprod Sci, 6. pp. 168–175. https://doi.org/10.4103/0974-1208.121400
Melmed S., Kleinberg D (2008) Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR eds. Williams textbook of endocrinology . 11th ed. Philadelphia: Saunders Elsevier; 185–261.
Modebe O. (1994) Hyperprolactinemia in oligospermic Nigerian males: effect of bromocriptine treatment Int J Fertil Menopausal Stud, 39. pp. 95–99.
Rosa De M., Ciccarelli A., Zarrilli S., Guerra E., Gaccione M., Di Sarno A. et al. (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males Clin Endocrinol (Oxf), 64, pp. 307–313. https://doi.org/10.1111/j.1365-2265.2006.02461.x
Colao A., Vitale G., Cappabianca P., Briganti F., Ciccarelli A., De Rosa M., et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis J Clin Endocrinol Metab, 89, pp. 1704–1711. https://doi.org/10.1210/jc.2003-030979
Rosa De M., Colao A., Di Sarno A., Ferone D., Landi M.L., Zarrilli S. et al. (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol, 138. pp. 286–293. https://doi.org/10.1530/eje.0.1380286
Bandyopadhyay A., Sen K., Chakrabarti N., Datta S. (2019) Galactocele of adult male breast: A cytopathologist’s perspective. Diagn Cytopathol. Feb;47(2):134–136. https://doi.org/10.1002/dc.24101
Molitch M.E. (2008) Drugs and prolactin Pituitary, 11. pp. 209–218. https://doi.org/10.1007/s11102-008-0106-6
Katznelson L., Klibanski A. (1997) Prolactinomas Cancer Treat Res, 89. pp. 41–55. https://doi.org/10.1007/978-1-4615-6355-6_3
Colao A., De Rosa M., Sarnacchiaro F., Di Sarno A., Landi M.L., Iervolino E., et al. (1996) Chronic treatment with CV 205–502 restores the gonadal function in hyperprolactinemic males Eur J Endocrinol, 135. pp. 548–552. https://doi.org/10.1530/eje.0.1350548
Singh P., Singh M., Cugati G., Singh A.K. (2011) Hyperprolactinemia: an often missed cause of male infertility J Hum Reprod Sci, 4. pp. 102–103. https://dx.doi.org/10.4103%2F0974-1208.86094
Nishimura K., Matsumiya K., Tsuboniwa N., Yamanaka M., Koga M., Miura H. Et al. (1999) Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects Arch Androl, 43. pp. 207–213. https://doi.org/10.1080/014850199262517
Mcquaid J.W., Tanrikut C. (2014) Physiology of testosterone. In: Mulhall JP, Hsiao W, editors. Men’s sexual health and fertility. A Clinician’s guide. New York: Springer Science and Business Media. https://doi.org/10.1007/978-1-4939-0425-9_3
Tsutsumi R., Webster N.J. (2009) GnRH pulsatility, the pituitary response and reproductive dysfunction Endocr J, 56. pp. 729–737. https://doi.org/10.1507/endocrj.k09e-185
Hair W.M., Gubbay O., Jabbour H.N., Lincoln G.A. (2002) Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol Hum Reprod.; 8:606–11. https://doi.org/10.1093/molehr/8.7.606
Klemcke H.G., Amador A.G., Bartke A. (1990) Hormonal regulation of testicular prolactin receptors and testosterone synthesis in golden hamsters Biol Reprod, 43, pp. 162–168. https://doi.org/10.1095/biolreprod43.1.162
Jabbour H.N., Lincoln G.A. (1999) Prolactin receptor expression in the testis of the ram: localisation, functional activation and the influence of gonadotrophins Mol Cell Endocrinol, 148, pp. 151–161. https://doi.org/10.1016/s0303-7207(98)00220-2
Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A. et al. (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab, 96, pp. 273–288. https://doi.org/10.1210/jc.2010-1692
Furigo IC, Suzuki MF, Oliveira JE et al. (2019) Suppression of Prolactin Secretion Partially Explains the Antidiabetic Effect of Bromocriptine in ob/ob Mice. Endocrinology. Jan 1;160(1):193–204. https://doi.org/10.1210/en.2018-00629
Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, Díez JJ. (2018) Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes. Horm Metab Res. Nov;50(11):791–796. https://doi.org/10.1055/a-0752-0741
Lazopoulos A., Krimiotis D., Schizas N.C. et al. (2018) Galactorrhea, mastodynia and gynecomastia as the first manifestation of lung adenocarcinoma. A case report. Respir Med Case Rep. Dec 4;26:146–149. https://dx.doi.org/10.1016%2Fj.rmcr.2018.12.001
Salhi H., Lahlou A., Dante M.L., El Ouahabi H., Boujraf S., Ajdi F. (2018) Stature-weight growth delays: Clinical and etiological aspects. J Family Med Prim Care. Sep-Oct;7(5):963–966. https://dx.doi.org/10.4103%2Fjfmpc.jfmpc_207_16
Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology. Evaluation of the azoospermic male: a committee opinion. (2018) Fertil Steril. May;109(5):777–782. https://doi.org/10.1016/j.fertnstert.2018.01.043
Maiter D. (2018) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42–50. https://doi.org/10.1159/000495775
Pinzone J.J., Katznelson L., Danila D.C., Pauler D.K., Miller C.S., Klibanski A. (2000) Primary medical therapy of micro- and macroprolactinomas in men J Clin Endocrinol Metab, 85 pp. 3053–3057. https://doi.org/10.1210/jcem.85.9.6798
RxList. Dostinex (cabergoline); 2016. Available at: https://www.rxlist.com/dostinex-drug.htm Accessed October 2017.
RxList. Cycloset (bromocriptine mesylate tablets), 2017. Available at: https://www.rxlist.com/cycloset-drug.htm Accessed October 2017.
Barlier A., Jaquet P. (2006) Quinagolide – a valuable treatment option for hyperprolactinaemia Eur J Endocrinol, 154. pp. 187–195. https://doi.org/10.1530/eje.1.02075
Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia N Engl J Med, 349. pp. 2023–2033. https://doi.org/10.1056/NEJMoa022657
